GE, iBio unite on plant-based production of vaccines and biologics

GE Healthcare and iBio ($IBIO) will partner to commercialize plant-based technologies for manufacturing biopharmaceuticals and vaccines. The pair already have a development and marketing agreement, which was announced in 2010. The new alliance combines iBio's plant-based vaccine manufacturing platform, iBioLaunch, with GE Healthcare's start-to-finish biopharmaceutical manufacturing technologies. Release

Suggested Articles

BN will use its proprietary MVA-BN platform to develop a vaccine against three strains of the potentially deadly mosquito-borne virus.

BN's cancer vaccine CV301 is already under evaluation with Keytruda in NSCLC and with Tecentriq in bladder cancer.

The two new grants will support development of universal flu and malaria vaccines leveraging CureVac’s RNActive mRNA-based platform.